PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes [PDF]
Clinical Cancer Research, 2021 Abstract Purpose: Therapeutic checkpoint inhibitors on tumor-infiltrating lymphocytes (TIL) are being increasingly utilized in the clinic. The T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory receptor expressed on T and natural killer cells. The TIGIT signaling pathway is
Travis Shaffer +2 more
openaire +2 more sources
Expression and Clinical Significance of TIGIT in Primary Breast Cancer
International Journal of General Medicine, 2023 Limin Tang,1 Min Sha,2 Ting Guo,2 Huimin Lu,2 Jingyu Qian,2 Qixiang Shao,1 Jun Ye2 1Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China; 2Department of Central Laboratory, The Affiliated ...
Tang L +6 more
doaj
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
OncoImmunology, 2018 The use of inhibitory checkpoint blockade in the management of glioblastoma has been studied in both preclinical and clinical settings. TIGIT is a novel checkpoint inhibitor recently discovered to play a role in cancer immunity.
Alice L. Hung +22 more
doaj +1 more source
Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection. [PDF]
, 2020 Mucosa-associated invariant T (MAIT) cell loss in chronic HIV-1 infection is a significant insult to antimicrobial immune defenses. Here we investigate the response of MAIT cells during acute HIV-1 infection utilizing the RV217 cohort with paired ...
Ananworanich, Jintanat +23 more
core
Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors [PDF]
, 1994 Background: Most patients with early stage triple negative breast cancer (TNBC) receive adjuvant chemotherapy. Activation of the immune system is associated with tumor response and may help identify TNBC with favorable outcome.
Alberto Ocaña +8 more
core +3 more sources
OncoImmunology, 2021 PD1 blockade to reinvigorate T cells has become part of standard of care for patients with NSCLC across disease stages. However, the majority of patients still do not respond.
Marina Martinez +7 more
doaj +1 more source
Expression of CD226 is associated to but not required for NK cell education [PDF]
, 2017 DNAX accessory molecule-1 (DNAM-1, also known as CD226) is an activating receptor expressed on subsets of natural killer (NK) and T cells, interacts with its ligands CD155 or CD112, and has co-varied expression with inhibitory receptors. Since inhibitory
Bernhardt, Günter +9 more
core +2 more sources
CD226 opposes TIGIT to disrupt Tregs in melanoma [PDF]
JCI Insight, 2018 CD4+ Tregs impede T cell responses to tumors. They express multiple inhibitory receptors that support their suppressive functions, including T cell Ig and ITIM domain (TIGIT). In melanoma patients, we show that Tregs exhibit increased TIGIT expression and decreased expression of its competing costimulatory receptor CD226 as compared with CD4+ effector ...
Julien Fourcade +13 more
openaire +2 more sources
Structural and functional characterization of a monoclonal antibody blocking TIGIT
mAbs, 2022 TIGIT is an immune checkpoint receptor that is expressed on subsets of activated T cells and natural killer (NK) cells. Several ligands for TIGIT, including poliovirus receptor (PVR), are expressed on cancer cells and mediate inhibitory signaling to ...
Bo-Seong Jeong +12 more
doaj +1 more source
Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence. [PDF]
, 2020 There is a growing body of literature demonstrating the importance of T cell exhaustion in regulating and shaping immune responses to pathogens and cancer.
Canter, Robert J +2 more
core